• Submitted by: Juana
• Health and Medicine
• 07 / 29 / 2015

---

The biotech Malaysian firm Bioven, which conducts clinical trials on third phase of a promising Cuban vaccine against cancer, plans to market in London after a fruitful collaboration with Cuba.
The relationship of the Caribbean country with the Bioven, in which the Malaysian government is one of its major shareholders, is an example of South-South cooperation, Elnartd Blanco, commercial manager of CIMAB, distributor  of the Center of Molecular Immunology (CIM by its Spanish acronym) , who created the vaccine, told Prensa Latina.
Since 2008, through an agreement with the CIM, Bioven is making the clinical development of the Cuban vaccine in Europe and parts of Asia and Oceania, said Blanco.
Since then, Bioven placed the drug -which targets non-small cell lung cancer- in larger post-test, and Stephen Drew, chief executive, said that from the Alternative Investment Market, the junior values market of London, can help speed up the commercial push.

source: www.cibercuba.com